Top Markets
Coin of the day
Voronoi, Inc. Voronoi, Inc.

Voronoi, Inc.

310210
Rangering i aksjer #6293
Voronoi, Inc., founded in 2015 and based in Incheon, South Korea, is a... Voronoi, Inc., founded in 2015 and based in Incheon, South Korea, is a biotechnology company dedicated to the research, development, and identification of small molecule kinase inhibitors. Its extensive product pipeline addresses various medical needs. Key candidates include VRN01, an oral leucine-rich repeat kinase 2 (LRRK2) inhibitor, being developed for glioblastoma multiforme, brain cancer, and pancreatic cancer. Treatments for lung cancer are represented by VRN07, VRN06, and VRN11, while VRN08 and VRN10 are in development for breast cancer. Additionally, VRN02 targets rheumatoid arthritis and atopic dermatitis. The company's pipeline further encompasses VRN04-1 for autoimmune conditions, VRN04-2 for multiple sclerosis and amyotrophic lateral sclerosis (ALS), VRN13 for pulmonary arterial hypertension, and VRN14 for challenging solid tumors.
Aksjekurs
$115.48
Markedsverdi
$2.12B
Endring (1 dag)
0.72%
Endring (1 år)
29.38%
Land
KR
Handel Voronoi, Inc. (310210)

Kategori

P/B-forhold for Voronoi, Inc. (310210)
P/B-forhold per 2026 TTM: 0
Ifølge Voronoi, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Voronoi, Inc. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH